Bevacizumab Efficiently Inhibits VEGF-Associated Cellular Processes in Equine Umbilical Vein Endothelial Cells: An In Vitro Characterization
Anti-VEGF agents were found to have clinical implications for the successful treatment of vascular-driven diseases in humans. In this study, a detailed biological characterization of bevacizumab in a variety of in vitro assays was carried out to determine the effect of bevacizumab on equine umbilica...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-10-01
|
| Series: | Veterinary Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2306-7381/10/11/632 |
| _version_ | 1797457546673389568 |
|---|---|
| author | Ulrike Lessiak Barbara Pratscher Alexander Tichy Barbara Nell |
| author_facet | Ulrike Lessiak Barbara Pratscher Alexander Tichy Barbara Nell |
| author_sort | Ulrike Lessiak |
| collection | DOAJ |
| description | Anti-VEGF agents were found to have clinical implications for the successful treatment of vascular-driven diseases in humans. In this study, a detailed biological characterization of bevacizumab in a variety of in vitro assays was carried out to determine the effect of bevacizumab on equine umbilical vein endothelial cells (EqUVEC). EqUVECs were harvested from umbilical cords of clinically healthy horses and exposed to different concentrations (1, 2, 4, 6, 8 mg/mL) of bevacizumab (Avastin<sup>®</sup>). Assays concerning the drug’s safety (cell viability and proliferation assay) and efficacy (cell tube formation assay, cell migration assay, and Vascular endothelial growth factor (VEGF) expression) were carried out reflecting multiple cellular processes. Bevacizumab significantly decreased VEGF expression at all concentrations over a 72 h period. No cytotoxic effect of bevacizumab on EqUVECs was observed at concentrations of 4 mg/mL bevacizumab or lower. Incubated endothelial cells showed delayed tube formation and bevacizumab efficiently inhibited cell migration in a dose-dependent manner. Bevacizumab potently inhibits VEGF-induced cellular processes and could be a promising therapeutic approach in vascular-driven diseases in horses. |
| first_indexed | 2024-03-09T16:23:36Z |
| format | Article |
| id | doaj.art-619263e7d4c3434486db56ccb8fe1d96 |
| institution | Directory Open Access Journal |
| issn | 2306-7381 |
| language | English |
| last_indexed | 2024-03-09T16:23:36Z |
| publishDate | 2023-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Veterinary Sciences |
| spelling | doaj.art-619263e7d4c3434486db56ccb8fe1d962023-11-24T15:10:23ZengMDPI AGVeterinary Sciences2306-73812023-10-01101163210.3390/vetsci10110632Bevacizumab Efficiently Inhibits VEGF-Associated Cellular Processes in Equine Umbilical Vein Endothelial Cells: An In Vitro CharacterizationUlrike Lessiak0Barbara Pratscher1Alexander Tichy2Barbara Nell3Department of Companion Animals and Horses, University of Veterinary Medicine Vienna, Veterinaerplatz 1, 1210 Vienna, AustriaDepartment of Companion Animals and Horses, University of Veterinary Medicine Vienna, Veterinaerplatz 1, 1210 Vienna, AustriaDepartment of Biomedical Sciences, University of Veterinary Medicine Vienna, Veterinaerplatz 1, 1210 Vienna, AustriaDepartment of Companion Animals and Horses, University of Veterinary Medicine Vienna, Veterinaerplatz 1, 1210 Vienna, AustriaAnti-VEGF agents were found to have clinical implications for the successful treatment of vascular-driven diseases in humans. In this study, a detailed biological characterization of bevacizumab in a variety of in vitro assays was carried out to determine the effect of bevacizumab on equine umbilical vein endothelial cells (EqUVEC). EqUVECs were harvested from umbilical cords of clinically healthy horses and exposed to different concentrations (1, 2, 4, 6, 8 mg/mL) of bevacizumab (Avastin<sup>®</sup>). Assays concerning the drug’s safety (cell viability and proliferation assay) and efficacy (cell tube formation assay, cell migration assay, and Vascular endothelial growth factor (VEGF) expression) were carried out reflecting multiple cellular processes. Bevacizumab significantly decreased VEGF expression at all concentrations over a 72 h period. No cytotoxic effect of bevacizumab on EqUVECs was observed at concentrations of 4 mg/mL bevacizumab or lower. Incubated endothelial cells showed delayed tube formation and bevacizumab efficiently inhibited cell migration in a dose-dependent manner. Bevacizumab potently inhibits VEGF-induced cellular processes and could be a promising therapeutic approach in vascular-driven diseases in horses.https://www.mdpi.com/2306-7381/10/11/632anti-VEGFequine umbilical vein endothelial cellsbevacizumabangiogenesis |
| spellingShingle | Ulrike Lessiak Barbara Pratscher Alexander Tichy Barbara Nell Bevacizumab Efficiently Inhibits VEGF-Associated Cellular Processes in Equine Umbilical Vein Endothelial Cells: An In Vitro Characterization Veterinary Sciences anti-VEGF equine umbilical vein endothelial cells bevacizumab angiogenesis |
| title | Bevacizumab Efficiently Inhibits VEGF-Associated Cellular Processes in Equine Umbilical Vein Endothelial Cells: An In Vitro Characterization |
| title_full | Bevacizumab Efficiently Inhibits VEGF-Associated Cellular Processes in Equine Umbilical Vein Endothelial Cells: An In Vitro Characterization |
| title_fullStr | Bevacizumab Efficiently Inhibits VEGF-Associated Cellular Processes in Equine Umbilical Vein Endothelial Cells: An In Vitro Characterization |
| title_full_unstemmed | Bevacizumab Efficiently Inhibits VEGF-Associated Cellular Processes in Equine Umbilical Vein Endothelial Cells: An In Vitro Characterization |
| title_short | Bevacizumab Efficiently Inhibits VEGF-Associated Cellular Processes in Equine Umbilical Vein Endothelial Cells: An In Vitro Characterization |
| title_sort | bevacizumab efficiently inhibits vegf associated cellular processes in equine umbilical vein endothelial cells an in vitro characterization |
| topic | anti-VEGF equine umbilical vein endothelial cells bevacizumab angiogenesis |
| url | https://www.mdpi.com/2306-7381/10/11/632 |
| work_keys_str_mv | AT ulrikelessiak bevacizumabefficientlyinhibitsvegfassociatedcellularprocessesinequineumbilicalveinendothelialcellsaninvitrocharacterization AT barbarapratscher bevacizumabefficientlyinhibitsvegfassociatedcellularprocessesinequineumbilicalveinendothelialcellsaninvitrocharacterization AT alexandertichy bevacizumabefficientlyinhibitsvegfassociatedcellularprocessesinequineumbilicalveinendothelialcellsaninvitrocharacterization AT barbaranell bevacizumabefficientlyinhibitsvegfassociatedcellularprocessesinequineumbilicalveinendothelialcellsaninvitrocharacterization |